The effects of concentrated pomegranate juice on inflammatory factors in type 2 diabetes

The effect of concentrated pomegranate juice consumption on lipid profile and inflammatory factors in patients with type 2 diabetes

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2013091614680N1

Enrollment

Registered

2013-11-22

Start date

2013-10-02

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes. Non-insulin-dependent diabetes mellitus

Interventions

50 gr concentrated pomegranate juice with lunch and dinner meals for 4 weeks.

Treatment - Other

50 gr concentrated pomegranate juice with lunch and dinner meals for 4 weeks

Eligibility

Sex/Gender

All

Age

25 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: male or female 25 to 60 years old; having type 2 diabetes at least 6 month. Exclusion criteria: pregnancy; lactation; cardiac; hepatic; respiratory and chronic renal diseases; acute or chronic inflammation; retinopathy; intake of antioxidant supplement; insulin therapy; sensitivity to concentrated pomegranate juice; change oral drug for controlling blood glucose were excluded.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Triglyceride. Timepoint: Baseline and after 4 weeks. Method of measurement: Spectrophotometry.;Total Cholesterol. Timepoint: Baseline and after 4 weeks. Method of measurement: Spectrophotometry.;HDL- Cholesterol. Timepoint: Baseline and after 4 weeks. Method of measurement: Spectrophotometry.;LDL- Cholesterol. Timepoint: Baseline and after 4 weeks. Method of measurement: Friedewald Formula.;HsCRP. Timepoint: Baseline and after 4 weeks. Method of measurement: Eliza.;TNF- a. Timepoint: Baseline and after 4 weeks. Method of measurement: Eliza.;IL-6. Timepoint: Baseline and after 4 weeks. Method of measurement: Eliza.;Adiponectin. Timepoint: Baseline and after 4 weeks. Method of measurement: Eliza.	—

Measure

Time frame

Triglyceride. Timepoint: Baseline and after 4 weeks. Method of measurement: Spectrophotometry.;Total Cholesterol. Timepoint: Baseline and after 4 weeks. Method of measurement: Spectrophotometry.;HDL- Cholesterol. Timepoint: Baseline and after 4 weeks. Method of measurement: Spectrophotometry.;LDL- Cholesterol. Timepoint: Baseline and after 4 weeks. Method of measurement: Friedewald Formula.;HsCRP. Timepoint: Baseline and after 4 weeks. Method of measurement: Eliza.;TNF- a. Timepoint: Baseline and after 4 weeks. Method of measurement: Eliza.;IL-6. Timepoint: Baseline and after 4 weeks. Method of measurement: Eliza.;Adiponectin. Timepoint: Baseline and after 4 weeks. Method of measurement: Eliza.

—

Secondary

Measure	Time frame
Fasting Blood Sugar. Timepoint: baseline and after 4 weeks. Method of measurement: Spectrophotometry.;Blood Pressure. Timepoint: Baseline and after 4 weeks. Method of measurement: Sphygmomanometer.;Body Mass Index. Timepoint: baseline and after 4 weeks. Method of measurement: calculate.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMaryam Zare

Ahvaz Jundishapour University of Medical Sciences

zare.m@ajums.ac.ir+98 31 1335 9090

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026